exhibit9914447l
Exhibit
99.1
Indivior Responds to Publication
of a Letter by Oaktree Capital Management to the Board of
Indivior
Richmond, VA, November 8, 2024 - Indivior PLC (NASDAQ / LSE: INDV)
the Board of Directors (the
"Board") of Indivior plc ("Indivior" or the "Company") notes the
publication today of a letter from Oaktree Capital Management LP
("Oaktree") to the Board of Indivior.
The Board has engaged actively with Oaktree in recent weeks on
these topics, and remains open-minded about all proposals to
enhance value creation. The Board is focused on acting in the best
interests of all shareholders as we continue to execute on our
strategy.
Indivior looks forward to further engagement with
Oaktree and other shareholders.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD), overdose and serious mental illnesses. Our vision
is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,000 individuals globally and its portfolio of
products is available in over 30 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
For Further Information
|
Investor Enquiries
|
Jason Thompson
|
VP,
Investor RelationsIndivior PLC
|
+1
804 402 7123
jason.thompson@indivior.com
|
|
|
|
Tim Owens
|
Director,
Investor Relations Indivior PLC
|
+1
804 263 3978
timothy.owens@indivior.com
|
|
Media Enquiries
|
Jonathan Sibun
|
Teneo
U.S.
Media Inquiries
|
+44
(0)20 7353 4200
+1
804 594 836
Indiviormediacontacts@indivior.com
|